Tara Spence
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tara Spence has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Eric McGinnis
Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine Vancouver General Hospital Vancouver British Columbia Canada
4 shared publications - Julia N. C. Parlow
Vancouver General Hospital
4 shared publications - Fatma AlBulushi
Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine Vancouver General Hospital Vancouver British Columbia Canada
2 shared publications - Nicolas Salcedo-Porras
Centre for Cell Biology, Development and Disease, Department of Biological Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
2 shared publications - Stephen Yip
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
2 shared publications Adrian M. Dubuc
Brigham and Women's Hospital, BWH Center for Advanced Molecular Diagnostics (CAMD), 75 Francis Street, BWH Shapiro Bldg 5th Floor, Boston MA 02115, USA
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by Clockwork Communications Inc. in Canadian Journal of Medical Specialties
- Vol. 2 (4)
Analytical superiority versus turnaround time: Why karyotyping persists amid the emergence of optical genome mapping in acute leukemia diagnostics
Optical genome mapping (OGM) provides high-resolution, genome-wide detection of structural and copy number variants in hematologic malignancies and has demonstrated increased diagnostic yield compared with conventional cytogenetics. Despite these advantages, karyotyping remains widely used in acute leukemia diagnostics. We examine the practical and analytical factors underlying continued reliance on conventional cytogenetic testing, with particular emphasis on turnaround time. At our institution, OGM has been implemented alongside karyotyping since 2023 and has been applied to more than 800 cases. While OGM improves detection of cryptic and complex genomic rearrangements, conventional karyotyping continues to deliver significantly faster preliminary and final results, which directly impact early clinical decision-making in acute leukemia. We describe our integrated diagnostic workflow and compare operational performance between modalities, highlighting trade-offs between genomic resolution and reporting speed. These findings support a complementary role for OGM while reinforcing the ongoing clinical necessity of rapid karyotyping in frontline acute leukemia diagnostics.
- 11 November 2026
- Published by Clockwork Communications Inc. in Canadian Journal of Medical Specialties
- Vol. 2 (4)
Open AccessAnalytical superiority versus turnaround time: Why karyotyping persists amid the emergence of optical genome mapping in acute leukemia diagnostics
Optical genome mapping (OGM) provides high-resolution, genome-wide detection of structural and copy number variants in hematologic malignancies and has demonstrated increased diagnostic yield compared with conventional cytogenetics. Despite these advantages, karyotyping remains widely used in acute leukemia diagnostics. We examine the practical and analytical factors underlying continued reliance on conventional cytogenetic testing, with particular emphasis on turnaround time. At our institution, OGM has been implemented alongside karyotyping since 2023 and has been applied to more than 800 cases. While OGM improves detection of cryptic and complex genomic rearrangements, conventional karyotyping continues to deliver significantly faster preliminary and final results, which directly impact early clinical decision-making in acute leukemia. We describe our integrated diagnostic workflow and compare operational performance between modalities, highlighting trade-offs between genomic resolution and reporting speed. These findings support a complementary role for OGM while reinforcing the ongoing clinical necessity of rapid karyotyping in frontline acute leukemia diagnostics.
- Open Access
- 6 November 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (11)
Complex and Cryptic KMT2A :: MLLT10 Rearrangements in Acute Myeloid Leukemia Resolved by Optical Genome Mapping
Accurate identification of KMT2A::MLLT10 fusions is essential for diagnostic classification and prognostication in acute myeloid leukemia and can guide therapeutic decision making. Detection of these fusions is diagnostically challenging due to the frequently cryptic and structurally complex nature of these events. In this study, we evaluated acute leukemia cases undergoing diagnostic workup with karyotyping and optical genome mapping (OGM), identified cases with KMT2A::MLLT10 fusions and retrospectively analyzed the structural events. During the period from September 2023 to April 2025, a total of five acute myeloid leukemia cases were identified which had a KMT2A::MLLT10 fusion. While OGM identified a KMT2A::MLLT10 rearrangement in all five cases, karyotype analysis showed no evidence of a rearrangement involving the KMT2A locus on 11q23 in four cases and fluorescence in situ hybridization (FISH) showed a normal signal pattern using a KMT2A break‐apart probe in interphase nuclei in three cases. Additionally, OGM revealed the complexity of the rearrangement events underlying fusion formation, generally including inversions ranging from less than 1 megabase to over 20 megabases in size along with variably sized deletions around the translocation breakpoints. Our study reveals that KMT2A::MLLT10 rearrangements are characterized by complex, multi‐break events with variable sizes of inversions of the translocated segments resulting in in‐frame fusions. These events were often difficult to detect by standard karyotype and interphase FISH, highlighting the value of high‐resolution methods like OGM in resolving these structurally complex events.
- 6 November 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (11)
Open AccessComplex and Cryptic KMT2A :: MLLT10 Rearrangements in Acute Myeloid Leukemia Resolved by Optical Genome Mapping
Accurate identification of KMT2A::MLLT10 fusions is essential for diagnostic classification and prognostication in acute myeloid leukemia and can guide therapeutic decision making. Detection of these fusions is diagnostically challenging due to the frequently cryptic and structurally complex nature of these events. In this study, we evaluated acute leukemia cases undergoing diagnostic workup with karyotyping and optical genome mapping (OGM), identified cases with KMT2A::MLLT10 fusions and retrospectively analyzed the structural events. During the period from September 2023 to April 2025, a total of five acute myeloid leukemia cases were identified which had a KMT2A::MLLT10 fusion. While OGM identified a KMT2A::MLLT10 rearrangement in all five cases, karyotype analysis showed no evidence of a rearrangement involving the KMT2A locus on 11q23 in four cases and fluorescence in situ hybridization (FISH) showed a normal signal pattern using a KMT2A break‐apart probe in interphase nuclei in three cases. Additionally, OGM revealed the complexity of the rearrangement events underlying fusion formation, generally including inversions ranging from less than 1 megabase to over 20 megabases in size along with variably sized deletions around the translocation breakpoints. Our study reveals that KMT2A::MLLT10 rearrangements are characterized by complex, multi‐break events with variable sizes of inversions of the translocated segments resulting in in‐frame fusions. These events were often difficult to detect by standard karyotype and interphase FISH, highlighting the value of high‐resolution methods like OGM in resolving these structurally complex events.
- Open Access
- 4 August 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 166 (2)
Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype
Objectives: MECOM rearrangements (MECOM-r) are high-risk events in myeloid neoplasms often cryptic or incompletely characterized by conventional karyotype analysis. We used optical genome mapping (OGM) to define the frequency and spectrum of MECOM-r in an unselected, consecutively collected cohort of individuals with high-grade myeloid neoplasms (HGMNs) and compared these findings with standard cytogenetic approaches. Methods: A total of 252 HGMN specimens, including 224 with definitive diagnoses of acute myeloid leukemia, were processed over a 2-year period using OGM, G-banded karyotyping and, in some cases, reflex fluorescence in situ hybridization (FISH) for the MECOM locus. Cases were retrospectively reviewed to determine whether the identification of MECOM-r by OGM refined diagnosis and/or prognosis. Results: Our diagnostic workflow identified MECOM-r in 12 cases (4.7%), only 6 of which were identified by combined karyotype and FISH analyses, the latter for suspected chromosome 3 abnormalities. The remaining 6 cases were cryptic due to normal karyotypes, highly complex karyotypes lacking apparent chromosome 3 involvement, or culture failure and thus were identified by OGM and reflex FISH. Furthermore, OGM clarified complex architectures, resolved genetic alterations, and identified diverse partner loci, including GATA2, THADA, MYC, PHACTR1, MB21D2, XR_001744423.2, IL12A-AS1, TRIM59, CDK6, and MSI2. Detection of these structural alterations prompted diagnostic and/or risk reclassification in 5 cases. Conclusions: Optical genome mapping doubled the detection rate and improved the structural resolution of MECOM-r by identifying rearrangements incompletely resolved or missed by conventional cytogenetics. Implementation of OGM showed that MECOM-r can be cryptic and frequently overlooked, highlighting the value of high-resolution testing in HGMNs.
- 4 August 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 166 (2)
Open AccessOptical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of MECOM rearrangements cryptic to conventional karyotype
Objectives: MECOM rearrangements (MECOM-r) are high-risk events in myeloid neoplasms often cryptic or incompletely characterized by conventional karyotype analysis. We used optical genome mapping (OGM) to define the frequency and spectrum of MECOM-r in an unselected, consecutively collected cohort of individuals with high-grade myeloid neoplasms (HGMNs) and compared these findings with standard cytogenetic approaches. Methods: A total of 252 HGMN specimens, including 224 with definitive diagnoses of acute myeloid leukemia, were processed over a 2-year period using OGM, G-banded karyotyping and, in some cases, reflex fluorescence in situ hybridization (FISH) for the MECOM locus. Cases were retrospectively reviewed to determine whether the identification of MECOM-r by OGM refined diagnosis and/or prognosis. Results: Our diagnostic workflow identified MECOM-r in 12 cases (4.7%), only 6 of which were identified by combined karyotype and FISH analyses, the latter for suspected chromosome 3 abnormalities. The remaining 6 cases were cryptic due to normal karyotypes, highly complex karyotypes lacking apparent chromosome 3 involvement, or culture failure and thus were identified by OGM and reflex FISH. Furthermore, OGM clarified complex architectures, resolved genetic alterations, and identified diverse partner loci, including GATA2, THADA, MYC, PHACTR1, MB21D2, XR_001744423.2, IL12A-AS1, TRIM59, CDK6, and MSI2. Detection of these structural alterations prompted diagnostic and/or risk reclassification in 5 cases. Conclusions: Optical genome mapping doubled the detection rate and improved the structural resolution of MECOM-r by identifying rearrangements incompletely resolved or missed by conventional cytogenetics. Implementation of OGM showed that MECOM-r can be cryptic and frequently overlooked, highlighting the value of high-resolution testing in HGMNs.
- Open Access
Comparative Evaluation of Comprehensive DNA and RNA Sequencing Platforms with Subsequent Clinical Validation for Hematolymphoid Malignancies
Background/Objectives: Genomic alterations play a central role in diagnosis, prognostication, and therapeutic planning for hematolymphoid malignancies. At our tertiary care center, frontline genomic testing relies on optical genome mapping, karyotyping, and fluorescence in situ hybridization, with targeted next-generation sequencing (NGS) performed externally. To provide more comprehensive genomic profiling, we evaluated two large-panel NGS platforms and subsequently performed a clinical validation of the selected assay. Methods: The Illumina PanHeme DNA panel and the SOPHiA Genetics Community Myeloid Solution were compared using 24 bone marrow aspirate specimens with previously characterized alterations, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variants (CNVs). The selected panel underwent full analytical validation using 60 specimens. Results: Both panels demonstrated excellent concordance for SNVs and indels, with comparable analytical performance and workflow. CNV calling with SOPHiA was notably strong. Platform selection was influenced by practical considerations, including panel content and cost, leading to a preference for further evaluation of the Illumina assay. Clinical validation of the Illumina PanHeme DNA panel, along with a complementary RNA Exome panel, was subsequently performed. Sequence variant detection showed 100% concordance with orthogonal testing, while CNV detection was variable, reflecting known limitations of targeted NGS. The RNA panel detected all expected fusion transcripts. Conclusions: These findings demonstrate robust analytical performance of both evaluated DNA panels. Clinical validation of the Illumina PanHeme DNA and RNA Exome assays supports their use for comprehensive molecular profiling of hematologic malignancies.
Open AccessComparative Evaluation of Comprehensive DNA and RNA Sequencing Platforms with Subsequent Clinical Validation for Hematolymphoid Malignancies
Background/Objectives: Genomic alterations play a central role in diagnosis, prognostication, and therapeutic planning for hematolymphoid malignancies. At our tertiary care center, frontline genomic testing relies on optical genome mapping, karyotyping, and fluorescence in situ hybridization, with targeted next-generation sequencing (NGS) performed externally. To provide more comprehensive genomic profiling, we evaluated two large-panel NGS platforms and subsequently performed a clinical validation of the selected assay. Methods: The Illumina PanHeme DNA panel and the SOPHiA Genetics Community Myeloid Solution were compared using 24 bone marrow aspirate specimens with previously characterized alterations, including single nucleotide variants (SNVs), insertions/deletions (indels), and copy number variants (CNVs). The selected panel underwent full analytical validation using 60 specimens. Results: Both panels demonstrated excellent concordance for SNVs and indels, with comparable analytical performance and workflow. CNV calling with SOPHiA was notably strong. Platform selection was influenced by practical considerations, including panel content and cost, leading to a preference for further evaluation of the Illumina assay. Clinical validation of the Illumina PanHeme DNA panel, along with a complementary RNA Exome panel, was subsequently performed. Sequence variant detection showed 100% concordance with orthogonal testing, while CNV detection was variable, reflecting known limitations of targeted NGS. The RNA panel detected all expected fusion transcripts. Conclusions: These findings demonstrate robust analytical performance of both evaluated DNA panels. Clinical validation of the Illumina PanHeme DNA and RNA Exome assays supports their use for comprehensive molecular profiling of hematologic malignancies.
- 20 January 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (4) , 377-388
Technical Validation and Prospective Clinical Utility of Optical Genome Mapping in Acute Leukemia Workup
- 20 January 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (4) , 377-388
Technical Validation and Prospective Clinical Utility of Optical Genome Mapping in Acute Leukemia Workup
- 7 January 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (3) , 248-261
Speed meets precision: rapid intraoperative diagnostics in neuro-oncologic surgery
- 7 January 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (3) , 248-261
Speed meets precision: rapid intraoperative diagnostics in neuro-oncologic surgery
- 22 August 2022
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 42 (3) , 451-468
Copy Number Analysis in Cancer Diagnostic Testing
- 22 August 2022
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 42 (3) , 451-468
Copy Number Analysis in Cancer Diagnostic Testing